Drug General Information
Drug ID	D01ZUV
Former ID	DNCL002334
Drug Name	GDC-0425
Indication	Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86]		Phase 1	[523494]
Company	Genentech
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Serine/threonine-protein kinase Chk1	Target Info	Modulator	[549773]
KEGG Pathway	Cell cycle
	p53 signaling pathway
	HTLV-I infection
	Viral carcinogenesis
Pathway Interaction Database	Fanconi anemia pathway
	p73 transcription factor network
	ATR signaling pathway
	Circadian rhythm pathway
	p53 pathway
Reactome	Activation of ATR in response to replication stress
	Processing of DNA double-strand break ends
	Presynaptic phase of homologous DNA pairing and strand exchange
	G2/M DNA damage checkpoint
	Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
WikiPathways	DNA Damage Response
	Signaling by SCF-KIT
	ATM Signaling Pathway
	Retinoblastoma (RB) in Cancer
	Integrated Pancreatic Cancer Pathway
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Cell Cycle
	Cell Cycle Checkpoints
	miRNA Regulation of DNA Damage Response
References
Ref 523494	ClinicalTrials.gov (NCT01359696) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma. U.S. National Institutes of Health.
Ref 549773	Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.